Novartis Articles
Sandoz/Novartis buy Oriel Therapeutics, gaining rights to portfolio of products targeting asthma and COPD
19 April 2010
Novartis’ MS drug Gilenia cuts relapse rates, moving it forward in race with Merck KGaA’s cladribine
13 April 2010
Antisoma plunges 72% after saying continuing late-stage NSCLC drug candidate development would be “futile”
29 March 2010
UK’s NICE “not minded” to recommend Novartis’ Glivec/Gleevec for GIST patients at risk of recurrence after surgery
24 March 2010
US President and FTC still believe legislation banning pay-to-delay settlements needed
19 March 2010
WHO suspends use of Sanofi-Aventis’ Shan5 vaccine; Novartis’ vaccine cleared in Europe
18 March 2010
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
New study highlights changes in the management of gout and hyperuricemia among US rheumatologists and PCPs
2 March 2010
One cheer for Pfizer’s Fablyn
26 February 2010
Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market
25 February 2010
US FDA warns Lilly on insulin API manufacturing violations and Roche and Abbott over HIV combo drug concerns
24 February 2010
UK patient group makes case for CML drugs Sprycel and Tasigna given initial “thumbs down” by the NICE
24 February 2010
AstraZeneca settles over transfer pricing in UK, agreeing to pay £505 million; GSK slumps on Avandia news
23 February 2010
Novartis’ Tasigna gets FDA priority review for early-stage CML and Gilenia for MS; also OK for meningitis vaccine Menveo
22 February 2010
US FDA calls for new safety controls on long-acting asthma drugs that could hit sales potential
19 February 2010
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
Targeted cancer drug market set to reach $51 billion by 2015, led by Pfizer; barriers to use of oral cancer drugs identified
19 February 2010
Ulcerative colitis drug market will nearly double to $2.1 billion in 2018 in top seven markets
15 February 2010
AstraZeneca’s CEO defends company’s stance in Bloomberg interview
15 February 2010
Analysts see positive future for Amgen’s bone metastases drug denosumab following strong Ph III data
10 February 2010
Licensing deals: Debiopharm/Novartis; Teva/Active Biotech; Qiagen on biomarker; Merck & Co/AnaptysBio; and Novavax/ROVI accord dropped
9 February 2010
UK’s NICE says “no” to Novartis’ Afinitor for advanced RCC and delays Sprycel and Tasigna; Scotland backs Alimta and Stelara
9 February 2010
Orphan drugs in Asia-Pacific: From designation to pricing, funding and market access
8 February 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Pharmaceutical M&A deals in 2009
4 February 2010
Japanese drug major Astellas’ 3rd quarter net profit slumps 47% as Prograf hit by generic competition
3 February 2010
Hypertension drug market will be constrained through 2018, due to few novel emerging therapies in the pipeline
3 February 2010
UK’s MHRA advice on immunosuppressant ciclosporin highlights risk of automatic substitution of generic drugs
2 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
Uptake of the first oral MS therapies will result in the market value peaking at $8.4 billion in 2013
1 February 2010
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Promising results for Novartis and Merck KGaA oral MS drug trials represent "shifting tide"
22 January 2010
Alcon Independent Director Committee slams Novartis offer as “grossly inadequate, offensive and disrespectful”
21 January 2010
Japanese Pharma market seeing more foreign entrants
21 January 2010
Republican victory in Massachusetts a blow for Obama health reform plans; not a happy first anniversary present
20 January 2010
Batch of Japanese drug approvals, including for Taiho, Daiichi Sankyo and three for Novartis
20 January 2010
WHO’s pandemic advisor strongly denies industry influence in “false flu pandemic fiasco;” GSK says same
18 January 2010
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
New year, new optimism for UK health care/life sciences sector?
15 January 2010
EU action on pharma patent “pay-to-delay” settlements - a legal opinion; US FTC also to review the subject
13 January 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
UK govt in talks with GlaxoSmithKline to offload swine flu vaccine stocks as pandemic fails to materialize
11 January 2010
Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013
8 January 2010
Novartis to buy Corthera for $120 million, plus up to $500 million on success of ADHF drug relaxin
23 December 2009
Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid
22 December 2009
Europe’s CHMP serves up negative opinion for Ark’s Cerepro and calls for ban on benfluorex drugs, but good news for B-MS, Sanofi, GSK, Novartis
21 December 2009
European Commission confirms further surprise inspections in the pharmaceutical sector
10 December 2009
Novartis aims to hold global position in oncology, with new drugs and indications, R&D meeting told
9 December 2009
US FDA delays Merck KGaA’s filing on MS drug cladribine
1 December 2009
European Commission tops a billion euros invested in the fight against the global AIDS epidemic; clears new pandemic flu vaccine use
1 December 2009
Generics will continue to dominate Central and Eastern European pharma markets until 2011
30 November 2009
Novartis, in cooperation with HHS, inaugurates $1 billion large-scale US based cell-culture influenza vaccine facility
26 November 2009
Good and bad news for Idera Pharmaceuticals
26 November 2009
Novartis strikes licensing deal with Incyte
26 November 2009
Cancer pain drug market, fueled by opioids, will increase from $2.3 billion in 2008 to $3.7 billion in 2018
25 November 2009
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
24 November 2009
Emerging compounds will drive modest growth in the MRSA drug market through 2018, says Decision Resources
24 November 2009
Meeting highlights from Europe’s CHMP November 16-19, 2009
23 November 2009
Pharmerging markets: China - Leaders, Followers and Latecomers
13 November 2009
Several bidders line up for Germany’s Ratiopharm
12 November 2009
Teva files suit against Momenta/Sandoz over Copaxone, OK for generic Prevacid in USA for Teva and Mylan
11 November 2009
Confederation of Indian Industry and US India Business Council enter health care partnership
6 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
Novartis to invest 1 billion to build largest pharma R&D institute in China in Shanghia
3 November 2009
Swiss Pharma riding the global crisis
30 October 2009
EU approves Novartis’ Ilaris for CAPS; AstraZeneca withdraws Zactima marketing applications
28 October 2009
Global H1N1 2009 flu vaccine market worth $ 7.03 billion by 2011
23 October 2009
Animal research deserves defending
22 October 2009
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
